Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
Progress seen in recent years against the HIV pandemic, including in rising numbers of people diagnosed and treated accompanied by dropping rates of incidence and death, […]
SYDNEY – When Merinda Sebayang was undergoing treatment for multidrug-resistant TB in Indonesia – a nation with the third highest tuberculosis burden in the world after […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
With a report showing that 2018 yielded the highest case numbers seen so far of a paralyzing condition largely among children who had been sick with […]